Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Astec LifesciencesNSE:ASTEC -2.28%75 Debt-to-EBITDA is 9.52 as of Mar. 2026, which is 514% above its 10-year median of 1.55. GuruFocus rates NSE:ASTEC with a GF Score™ of 75/100 and a GF Value™ of ₹1,003.75 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 203 Agriculture companies, Astec Lifesciences ranks worse than 492610.34% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Astec Lifesciences's Debt-to-EBITDA or its related term are showing as below:
NSE:ASTEC'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -773.89 Med: 1.55 Max: 3.84
Current: -289.74
During the past 13 years, the highest Debt-to-EBITDA Ratio of Astec Lifesciences was 3.84. The lowest was -773.89. And the median was 1.55.
NSE:ASTEC's Debt-to-EBITDA is ranked worse than 100% of 203
companies
in the Agriculture industry
Industry Median: 2.08
vs NSE:ASTEC: -289.74
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Astec Lifesciences Debt-to-EBITDA Related Terms
Astec Lifesciences Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Astec Lifesciences's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ASTEC vs CTVA, CF, MOS: Debt-to-EBITDA Comparison
For the Agricultural Inputs subindustry, Astec Lifesciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astec Lifesciences Debt-to-EBITDA vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Astec Lifesciences's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Astec Lifesciences's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Astec Lifesciences (NSE:ASTEC) has a Debt-to-EBITDA of 9.52 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Astec Lifesciences. This is 514% above median its historical median of 1.55. According to the industry distribution chart, Astec Lifesciences ranks #999999 out of 203 companies in the Agriculture industry.
Is Astec Lifesciences' Debt-to-EBITDA too high?
Astec Lifesciences' current Debt-to-EBITDA of 9.52 is 514% above median its 10-year median of 1.55. The Agriculture industry median Debt-to-EBITDA is 2.08. Astec Lifesciences' value of 9.52 is 357.7% above this industry median. Based on the distribution chart, Astec Lifesciences ranks #999999 out of 203 companies in the Agriculture industry, which is in the bottom quartile relative to peers. Overall, Astec Lifesciences has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astec Lifesciences' Debt-to-EBITDA compare to CTVA and CF?
According to the Agriculture industry distribution chart, Astec Lifesciences ranks #999999 out of 203 companies for Debt-to-EBITDA. This places Astec Lifesciences in the lower half of its industry. The industry median Debt-to-EBITDA is 2.08. Astec Lifesciences' value of 9.52 is 357.7% above this benchmark. While the company's 10-year median is 1.55 vs. the industry median of 2.08, Astec Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for an Agriculture company?
The median Debt-to-EBITDA among Agriculture companies is 2.08, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astec Lifesciences's current Debt-to-EBITDA of 9.52 is 357.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Astec Lifesciences. For the Agriculture industry, the median Debt-to-EBITDA is 2.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astec Lifesciences's current Debt-to-EBITDA is 9.52, which is 514% above median its own 10-year median of 1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astec Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Astec Lifesciences (NSE:ASTEC) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹1,003.75, compared to a current price of ₹649.45 — trading 35.3% below its estimated fair value. The current Debt-to-EBITDA is 9.52, which is 514% above median its 10-year median of 1.55 and 357.7% above the Agriculture industry median of 2.08. Astec Lifesciences' overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Astec Lifesciences (NSE:ASTEC), the current Debt-to-EBITDA is 9.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astec Lifesciences (NSE:ASTEC) Overvalued in 2026?
Based on GuruFocus' analysis, Astec Lifesciences stock appears to be undervalued.
The current stock price of ₹649.45 is trading 35.3% below its estimated GF Value™ of ₹1,003.75.
GuruFocus considers Astec Lifesciences to be Significantly Undervalued.
Key valuation signals for NSE:ASTEC:
Debt-to-EBITDA: 9.52 (514% above median its 10-year median of 1.55)
GF Value™: ₹1,003.75 vs. price of ₹649.45 (35.3% below fair value)
Industry Position: 357.7% above the Agriculture median (#999999 of 203)
No single metric tells the full story. See the NSE:ASTEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astec Lifesciences Ltd manufactures & distributes a wide range of Agrochemical active ingredients and pharmaceutical intermediates. The company's products include agrochemicals, such as Triazole Fungicides, Herbicides, and Insecticides. The company is also into Intermediates & Specialty chemicals. Geographically, all the operations of the firm function through India; however, its products are sold in the Indian and overseas markets. It operates in the business segment of Agrochemicals and has a business presence in India and outside India.
75GF Score
Get the complete analysis for NSE:ASTEC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ASTEC has been successfully added to your 
